Publications
AARDEX Group announces the opening of a new office in the U.S.
By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems. Joe Keenan will lead the business development for the pharma and biotech industry in North America. With over 70% of AARDEX’s customers based in the U.S., this new office will support…
Read MoreUsing data science to detect key changes in medication intake behaviors.
Electronic monitoring, a digital technology based on smart packages, enables the most objective and precise adherence monitoring. By using an evidence-based digital adherence monitoring system, Sponsors and HCPs improve drug efficacy by managing patient adherence to the medications. In this Medium article (the online publishing platform), AARDEX presents the latest results from its data science…
Read MoreHow smart packages enable digital medication adherence monitoring for successful clinical trials?
50 % of patients involved in clinical trials do not take their medication as prescribed, resulting in underestimated drug efficacy and delayed approval of the investigational product. Poor medication adherence is thus a threat to drug development. Stop using unreliable methods to assess medication adherence and maximize the chances of success in your clinical trials…
Read MoreView or review our April 15 webinar on “SMART Medication Adherence Monitoring Improving Speed and Accuracy of Clinical Trials”
The webinar “SMART Medication Adherence Monitoring – Improving Speed and Accuracy of Clinical Trials“, held on April 15, was co-organized with our partner WestRock. Bernard Vrijens, Scientific Lead of AARDEX, has discussed the challenges of patient non adherence to medications in clinical trials.
Read MoreHow the EMERGE guideline on medication adherence can improve the quality of clinical trials
Recently, the FDA (Mar 2019) and the EMA (Feb 2020) have finalized guidances to monitor and mitigate the risk of patient non-adherence to the treatments tested in clinical trials. Under the auspices of the International Society for Medication Adherence (ESPACOMP), an international panel of experts established a set of reporting guidelines (EMERGE). In this newest publication,…
Read MoreAs the world leader in digital medication adherence monitoring for successful clinical trials, AARDEX is proud to announce its collaboration with 4 Belgian/Swiss financial partners to assist company’s growth.
SRIW, Sowalfin, Noshaq and CCF (Centre de Cautionnement et de Financement du Valais) are now part of the AARDEX Adventure.
Read MoreAARDEX’s scientific lead Bernard Vrijens is a panelist of the FDA and Duke-Margolis public meeting to explore the state of the science of clinical research evaluating medication adherence on December 10, 2019
Medication adherence—the extent to which patients take medications as prescribed in agreement with their health care provider—is an ongoing public health priority, given that improved adherence can lead to better clinical outcomes.
Read MoreAARDEX is collaborating with Pfizer to implement MEMS® in the FORWARD National Databank for Rheumatic Diseases to derive real world evidence adherence data.
Read more on recent MTX adherence publication
Read MoreImportant milestone in managing adherence to anti-osteoporosis treatment
AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.
Read MoreA Six Sigma framework to successfully manage medication adherence
Discover our CEO’s last publication in the British Journal of Clinical Pharmacology
Read More